Bupropion Hydrobromide Extended-Release for MDD and TRD

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD) using bupropion hydrochloride often result in inadequate therapeutic responses and side effects such as anxiety, agitation, and insomnia, limiting the tolerable dose for patients. Additionally, existing treatments for TRD, like Spravato, come with serious risks and inconvenient administration requirements.

Innovation Solution

Administering bupropion hydrobromide in extended-release form, which has demonstrated improved clinical efficacy and reduced side effects compared to bupropion hydrochloride, thereby offering a more effective and safer treatment option for MDD and TRD.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If bupropion hydrochloride is used to treat MDD and TRD, then therapeutic effect is achieved, but side effects such as anxiety, agitation, and insomnia occur, limiting the tolerable dose

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects (anxiety, agitation, insomnia)

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameter of bupropion from hydrochloride salt to hydrobromide salt formulation. This parameter change results in improved therapeutic efficacy and reduced side effects, allowing patients to tolerate higher doses without experiencing excessive anxiety, agitation, or insomnia.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If conventional TRD treatments like Spravato are used, then treatment resistance is addressed, but serious risks and inconvenient administration requirements occur

Engineering Contradiction:

Improvetreatment effectiveness for TRDVSAvoidserious risks and administration inconvenience

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the salt formulation parameter of bupropion from hydrochloride to hydrobromide, creating an extended-release formulation that provides effective TRD treatment without the serious risks and administration inconveniences associated with conventional treatments like Spravato.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If bupropion hydrochloride extended-release is used, then depression treatment is provided, but inadequate therapeutic response occurs in treatment-resistant patients

Engineering Contradiction:

Improvedepression treatment efficacyVSAvoidtherapeutic response

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent changes the salt formulation from hydrochloride to hydrobromide, which improves therapeutic response reliability in treatment-resistant depression patients while maintaining treatment efficacy.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250177326A1Therapeutic methods using bupropion hydrobromide

Publication Date: 2025.06.05 PRICE RICHARD LOUIS

AI summary

Disclosed are methods of treating a patient having Major Depressive Disorder (MDD) or Treatment Resistant Depression (TRD). The methods include administering to the patient a therapeutically effective amount of bupropion hydrobromide in extended-release form. The methods are more therapeutically effective in treating MDD or TRD than administration of an equivalent plasma dose of bupropion hydrochloride in extended-release form. In addition or alternatively, the therapeutically effective amount of bupropion hydrobromide reduces the incidence of one or more adverse events (anxiety, agitation and/or insomnia), when compared to the administration of the equivalent plasma dose of bupropion hydrochloride in extended-release form.